Clinical Trial

Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

Name: Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL — clinical trial record (NCT06874946)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Phase I/II

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-03-08.

Trial Details

NCT Number	NCT06874946
Lead Sponsor	Peking University People's Hospital Collaborators: Hebei Senlang Biotechnology Inc., Ltd.
Conditions	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma, PTCL
Enrollment	30 participants
Start Date	2025-02-14
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-07